SIOX
Closed
Sio Gene Therapies Inc
0.478
+0.008 (+1.70%)
Last Update: 07 Feb 2024 23:59:00
Yesterday: 0.47
Day's Range: 0. - 0.
Send
sign up or login to leave a comment!
When Written:
0.415
Sio Gene Therapies Inc is a biotechnology company that focuses on developing gene therapies for neurological disorders. The company was founded in 2018 and is headquartered in New York, USA.
Sio Gene Therapies is developing gene therapies for a range of neurological disorders, including Parkinson's disease, Huntington's disease, and ALS (amyotrophic lateral sclerosis). The company's lead product candidate is AXO-Lenti-PD, a gene therapy for Parkinson's disease that is currently in Phase 2 clinical trials.
Sio Gene Therapies is also developing a gene therapy for Huntington's disease, called AXO-HTT, which is currently in preclinical development. The company is also exploring gene therapies for other neurological disorders, including Alzheimer's disease and rare genetic disorders.
Sio Gene Therapies is focused on using its proprietary gene therapy platform to develop treatments that can address the underlying causes of neurological disorders. The company's platform is designed to deliver therapeutic genes to the brain and nervous system, with the goal of restoring normal function and improving patient outcomes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sio Gene Therapies is developing gene therapies for a range of neurological disorders, including Parkinson's disease, Huntington's disease, and ALS (amyotrophic lateral sclerosis). The company's lead product candidate is AXO-Lenti-PD, a gene therapy for Parkinson's disease that is currently in Phase 2 clinical trials.
Sio Gene Therapies is also developing a gene therapy for Huntington's disease, called AXO-HTT, which is currently in preclinical development. The company is also exploring gene therapies for other neurological disorders, including Alzheimer's disease and rare genetic disorders.
Sio Gene Therapies is focused on using its proprietary gene therapy platform to develop treatments that can address the underlying causes of neurological disorders. The company's platform is designed to deliver therapeutic genes to the brain and nervous system, with the goal of restoring normal function and improving patient outcomes.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








